Appropriate diversification of cellular lineages from multi-potent progenitors is essential for normal development and homeostasis. The specification of erythroid and megakaryocytic lineages represents an especially vital developmental event whose molecular regulation remains incompletely defined. We now demonstrate the role of Rgs18, a GTPase-activating protein and transcriptional target of the repressor Gfi1b, in regulating these processes in mouse and human cells. Gfi1b stringently represses Rgs18 expression in erythroid cells, whereas, during megakaryocytic differentiation, declining Gfi1b levels facilitate a robust induction of Rgs18. Concordantly, alterations in Rgs18 expression produce disparate outcomes by augmenting megakaryocytic and potently suppressing erythroid differentiation and vice versa. These phenotypes reflect the differential impact of Rgs18 on signaling through p38 MAPK family proteins, and ERK1 and ERK2 (also known as MAPK3 and MAPK1, respectively) in the two lineages, which in turn alter the balance between the mutually antagonistic transcription factors Fli1 and Klf1. Overall, these results identify Rgs18 as a new and crucial effector of Gfi1b that regulates downstream signaling and gene expression programs to orchestrate erythro-megakaryocytic lineage choices. This dual role of Rgs18 in reciprocally regulating divergent lineages could exemplify generic mechanisms characteristic of multiple family members in different contexts.
INTRODUCTION
Growth factor independence 1b (Gfi1b) is a zinc-finger transcriptional repressor that is essential for the generation of the erythroid and megakaryocytic lineages (Foudi et al., 2014; Saleque et al., 2002) , and is also required for lymphoid development (Doan et al., 2004; Schulz et al., 2012; van der Meer et al., 2010) . Although Gfi1b is also moderately expressed in several other tissues, including non-hematopoietic ones (Tong et al., 1998; Vassen et al., 2007) , the embryonic lethality resulting from the severe anemia following its germline deletion (Saleque et al., 2002) has, to date, precluded the analysis of its function in other developmental contexts. Dysregulation of Gfi1b and its paralog Gfi1 are also observed in various hematopoietic and non-hematopoietic malignancies (Elmaagacli et al., 2007; Khandanpour et al., 2012; Northcott et al., 2014; Vassen et al., 2009; Wallis et al., 2003) .
Gfi1 and Gfi1b mediate transcriptional repression of cognate gene targets by binding to the DNA motif TAAATCAC(A/T)GCA (Grimes et al., 1996; Tong et al., 1998) and recruiting chromatin modifiers and co-repressors such as lysine-specific demethylase 1 (LSD1, also known as KDM1A), the REST corepressors 1 and 2 (Rcor1 and Rcor2), histone deacetylase 1 and 2 (HDAC1 and HDAC2) and histone methyl transferases, such as G9a (also known as EHMT2) and SUV39H1 (Duan et al., 2005; Saleque et al., 2007; Upadhyay et al., 2014; Vassen et al., 2006) . The various histone modifications catalyzed by these factors -deacetylation by HDACs, H3K4 demethylation by LSD1 and H3K9 methylation by G9a and SUV39H1 -then lead to stable silencing of the Gfi1 and Gfi1b transcriptional targets in cells (Saleque et al., 2002; van der Meer et al., 2010) . Of these co-factors, LSD1 is especially important for Gfi1b function, as shown by the fact that the majority of Gfi1b transcriptional targets (∼80%) are also common to LSD1 in erythroid cells (Saleque et al., 2007) . This indicates that LSD1 likely acts as an obligate cofactor of Gfi1b at most targets.
Despite recognition of the essential mechanism of Gfi1b-mediated transcriptional repression, the repertoire of its major gene targets, and their contributions to the processes mediated by this factor and to hematopoietic or other developmental processes are largely unknown. In order to identify relevant gene targets that are major effectors of Gfi1b function, chromatin immunoprecipitation screens (ChIP-on-chip) were previously performed with antibodies against Gfi1b, LSD1 and Rcor1-CoREST in erythroid cells, leading to the identification of >600 putative common ChIP targets (Saleque et al., 2007) . To further determine the regulation of these targets by Gfi1b, LSD1 or Rcor1, expression profiling was performed in control versus LSD1-inhibited erythroid cells, given that depletion of LSD1 had previously been shown to upregulate known Gfi1b gene targets (including itself ) in erythroid cells (Saleque et al., 2007) . This combination of ChIP and microarray profiling screens uncovered the relative hierarchy of Gfi1b-LSD1 targets according to their extent of deregulation upon LSD1 depletion. One such gene highly upregulated in LSD1-knockdown erythroid cells was the signaling molecule regulator of G protein signaling 18 (Rgs18).
Rgs18 is a member of a large family (>30 members) of GTPaseactivating proteins (GAPs) that are known to accelerate the rate of GTP hydrolysis by α subunits of heterotrimeric G proteins, thereby controlling the duration and intensity of G-protein-coupled receptor (GPCR) activation and downstream signaling (Bansal et al., 2007; Kach et al., 2012) . This signaling molecule is highly expressed in megakaryocytes, platelets and in hematopoietic progenitors of the myeloerythroid lineage (Gagnon et al., 2002; Louwette et al., 2012; Park et al., 2001; Yowe et al., 2001) . Although Rgs18 is the most abundantly expressed Rgs protein in platelets, other family members, such as Rgs6, Rgs10 and Rgs16, are also known to be expressed in this lineage (Kim et al., 2006) . Rgs18 has been previously shown to bind both Gα q and Gα i proteins in megakaryocytes (Nagata et al., 2001) , and to act as a positive regulator of megakaryopoiesis (Delesque-Touchard et al., 2014; Louwette et al., 2012) . In contrast, it serves as a negative regulator of platelet function, and limits platelet aggregation and activation (Alshbool et al., 2015; Brass and Ma, 2012; Gegenbauer et al., 2012) .
Unlike its known functions in megakaryopoiesis and platelet activation, neither the expression nor the role of Rgs18 in erythroid cells (if any) has to date been documented. Therefore, following the identification of the Rgs18 promoter as a potential target of the Gfi1b-LSD1-Rcor1 transcriptional repressor triad in erythroid cells, we interrogated the expression and regulation of this factor by Gfi1b and LSD1 in both erythroid and megakaryocytic cells. Subsequently, we altered Rgs18 levels in these cells and determined the phenotypic consequences and molecular changes associated with these manipulations. Surprisingly, these experiments demonstrated that, in addition to enhancing megakaryopoiesis, Rgs18 expression potently suppressed erythroid differentiation and that these phenotypes resulted from differential regulation of mitogen-activated protein kinase (MAPK) signaling by Rgs18 in the two lineages. These signaling pathways, in turn, modulated relative expression of the mutually antagonistic cell-fate-specifying transcription factors, erythroid Kruppel-like factor (Eklf ) or Kruppel-like factor 1 (Klf1), and friend leukemia integration [site] 1 (Fli1), thus determining phenotypic outcomes. Moreover, the reduced differentiation produced upon Rgs18 inhibition could be reversed by ectopic expression of Fli1 demonstrating its role downstream of Rgs18. Therefore, these results establish Rgs18 as a new and crucial transcriptional target of Gfi1b, which, together with its repressor, regulates the reciprocal regulation of erythromegakaryocytic lineage specification.
RESULTS

Lineage-specific regulation of Rgs18 by Gfi1b and LSD1
A combination of ChIP-on-chip and expression profiling screens (Saleque et al., 2007) has revealed that the Rgs18 promoter is a prominent target locus for Gfi1b-LSD1-Rcor1. Examination of Rgs18 promoter sequences obtained from the mouse promoter arrays of these ChIP-on-chip screens (Chowdhury et al., 2013; Saleque et al., 2007) revealed the presence of quasi-consensus (AAATCT) and consensus (AAATCA) Gfi1-and Gfi1b-binding sites (Tong et al., 1998) in the 5′ untranslated region (UTR) and proximal protein coding regions of Rgs18, respectively (Fig. S1 ). Given that Gfi1b and LSD1 generally repress their gene targets (Saleque et al., 2007; Upadhyay et al., 2014) , we first monitored expression of Rgs18, Gfi1b, LSD1 and β-actin (as loading control) in immature and mature erythro-megakaryocytic cells. Curiously, Rgs18 was found to be low in the megakaryoblastic cell line L8057 (uninduced), in keeping with strong Gfi1b and LSD1 expression in these cells, but was strongly upregulated upon phorbol-esterinduced differentiation of these cells to megakaryocytes (Ishida et al., 1993) owing to a sharp decline in Gfi1b and LSD1 levels in the induced cells (Fig. 1A) . Expression of Gfi1b was strong in uninduced proerythroblast-like murine erythroleukemia (MEL) cells and increased further in DMSO-induced MEL cells, which resemble orthochromatic erythroblasts (Friend et al., 1971) (Fig. 1A) . By contrast, Rgs18 expression, which was modest in immature erythroid cells to begin with, exhibited a further reciprocal decline during maturation. As reported previously (Upadhyay et al., 2014) , LSD1 levels remained approximately uniform during maturation of these cells. To confirm association of Gfi1b and LSD1 with the abovementioned Gfi1-and Gfi1b-binding sites, ChIP followed by quantitative real-time PCR (ChIP-qPCR) was performed in both uninduced and induced erythroid (MEL) and megakaryocytic (L8057) cells (Fig. 1B,C) . The observed enrichment of Gfi1b and LSD1 on Rgs18 promoter segments corresponded entirely with their total protein levels in these cells. Gfi1b and LSD1 showed substantial enrichment on both Gfi1b-binding elements in uninduced L8057 cells but greatly reduced enrichment in the megakaryocyte-like induced L8057 cells. In contrast, marginally higher enrichment of these proteins was observed in mature (induced) versus immature (uninduced) erythroid (MEL) cells (Fig. 1B,C) . Surprisingly, the upstream 'semi-consensus' Gfi1b-binding element consistently showed greater enrichment for Gfi1b and LSD1 relative to the downstream 'consensus' element defined by previous reports (Tong et al., 1998) in ChIP assays in both lineages, demonstrating the relatively greater affinity of the upstream site for these proteins.
The repression of the Rgs18 promoter following its recruitment of LSD1 was then demonstrated by upregulation of Rgs18 expression in immature erythroid and megakaryocytic cells upon LSD1 inhibition (Fig. S1B ), although this occurred to differing extents in the two cell types (Fig. 1D) . Overall, these experiments demonstrated inverse expression patterns of Rgs18 and Gfi1b-LSD1 in erythro-megakaryocytic cells resulting from differential repression of Rgs18 by Gfi1b and LSD1 in the two lines.
Given that auto-repression of the Gfi1b promoter by itself (Saleque et al., 2007; Vassen et al., 2005) prevents effective inhibition of this factor by short hairpin RNA (shRNA)-mediated mechanisms, we were unable to replicate these results for Gfi1b. Instead, to confirm analogous repression of Rgs18 by Gfi1b in primary cells, their mRNA levels were monitored in control (wildtype and heterozygous) versus Gfi1b mutant cells. First, we determined Gfi1b and Rgs18 expression in total embryonic day 12.5 (e12.5) fetal liver cells from all three genotypes, given that wild-type e12.5 fetal livers are predominantly erythroid in composition, with ∼80% of cells having cell-surface glycophorin A (i.e. Ter119 antigen) a marker of mature erythroid cells (Fig. S1C ), in addition to having limited numbers of hematopoietic stem cells (HSCs), megakaryocyte-erythroid progenitors (MEPs) and megakaryocyte progenitors. Consistent with the indistinguishable phenotypes of wild-type versus Gfi1b +/− fetal livers, as reported previously (Saleque et al., 2002) , we observed a marginal decrease in Gfi1b and a similarly modest (∼20%) increase in Rgs18 mRNA levels in the heterozygous cells relative to wild-type controls (Fig. 1E ). In contrast, complete absence of Gfi1b in the homozygotes produced a substantial elevation of Rgs18 mRNA relative to wild-type cells in this primarily erythroid tissue (Fig. 1E) .
Next, to investigate the expression of Gfi1b and Rgs18 in primary megakaryocytes, we cultured wild-type e12.5 fetal liver cells with megakaryocytic cytokines to preferentially expand this lineage, which is under-represented at this stage of development (Zhang et al., 2003) . Differentiation of fetal liver progenitors to megakaryocytes was monitored by visual inspection and profiling for the megakaryocytic differentiation marker glycoprotein IIb (GPIIb, also known as CD41 or ITGA2B) (Fig. 1F) . Differentiation of wild-type progenitors into megakaryocytes was accompanied by a gradual decline in Gfi1b, and a concomitant and reciprocal increase in Rgs18 expression (Fig. 1F) , demonstrating progressively attenuated repression of the Rgs18 promoter upon decreasing Gfi1b expression. In contrast, although Rgs18 levels were higher in
Gfi1b
−/− fresh (day 0) total fetal liver cells relative to controls (which are largely erythroid in nature), it remained unchanged upon differentiation of mutant cells along the megakaryocyte lineage relative to that observed on day 0 (Fig. 1G ). This lack of a net increase in Rgs18 message levels in Gfi1b −/− cells relative to the day 0 control confirmed minimal or no repression of Rgs18 by Gfi1b during megakaryocytic differentiation and therefore no noticeable rise in Rgs18 expression in the absence of Gfi1b, unlike the increase seen in wild-type cells. The results depicted in Fig. 1 collectively demonstrate dose-dependent and differential repression of Rgs18 by Gfi1b and its cofactor LSD1 in erythroid versus megakaryocytic cells resulting in their reciprocal expression in the two lineages.
Antagonistic functions of Rgs18 in erythroid and megakaryocytic development
Given that Rgs18 is expressed in both erythroid and megakaryocytic cells, we next interrogated its role in their differentiation. Rgs18 expression was manipulated in fetal liver progenitors and cell lines by shRNA-mediated inhibition and cDNA transfection (i.e. protein overexpression). As per previous reports (Delesque-Touchard et al., 2014; Louwette et al., 2012) , inhibition of Rgs18 similarly retarded megakaryocytic differentiation of fetal liver progenitors cultured in vitro ( Fig. 2) and differentiation of the murine cell line L8057 induced with 12-O-tetradecanoylphorbol-13-acetate (TPA) (Fig. S2 ). This effect was demonstrated by a decrease in the expression of differentiation markers relative to a housekeeping gene (HPRT) ( Fig. 2A) , a reduction in the number of cells positive for acetylcholineesterase (a mouse megakaryocyte marker) (Fig. 2D ) and a diminution in the number of cells displaying the mature megakaryocytic cell surface markers CD9 and CD41 (Fig. 2E) . The reverse result, namely augmentation of differentiation, was obtained upon overexpression of Rgs18 in this lineage (Fig. 2B,D,E; Fig. S2 ). These results confirmed previous reports documenting the stimulatory role of Rgs18 in megakaryocytic differentiation (Delesque-Touchard et al., 2014; Louwette et al., 2012) .
In sharp contrast to the above phenotype, manipulation of Rgs18 produced exactly the opposite outcome in both primary erythroid cells and the murine MEL cell line ( Fig. 3; Fig. S2 ). Rgs18 inhibition produced a marked increase (Fig. 3A,C,D; Fig. S2F-I ), and overexpression a commensurate decrease, in differentiation ( Fig. 3B-D) as judged from differentiation marker analysis, benzidine staining (for heme positivity) and relative expression of the surface markers Ter119 versus c-Kit (a common marker of uncommitted progenitors). These results demonstrate a hitherto unknown function of Rgs18 in effectively inhibiting erythroid differentiation.
To confirm the validity of the Rgs18-knockdown phenotypes and rule out shRNA-mediated off-target effects, we overexpressed the protein-coding segment of Rgs18 cDNA in L8057 and MEL cells depleted for endogenous Rgs18 with shRNAs targeting the 3′UTR of the native transcript but that do not target the recombinant transcript. Following induction with TPA and DMSO, respectively, the cells expressing Rgs18 shRNAs and cDNAs were 'rescued' of their Rgs18 depletion phenotypes and reverted to the control state (Fig. S2E,I ), confirming the fidelity of the Rgs18-knockdown phenotypes.
To reiterate the analogous effect of Rgs18 on fetal liver hematopoietic progenitors, lineage-negative (Lin − ) c-Kit + cells comprising HSCs, MEPs and other undifferentiated progenitors were sorted out from e12.5 fetal livers (Fig. 4A) , transduced with Rgs18 shRNAs and cDNAs, and simultaneously co-cultured with cytokines promoting both lineages. These results further confirmed the stimulatory effect of Rgs18 expression on megakaryocytic, and suppressive effect on erythroid, differentiation in a progenitor population subjected to mixed culture conditions (Fig. 4B) .
Finally, to delineate the effects of Rgs18 expression in human cells, Rgs18 cDNA was expressed in the human multipotent hematopoietic cell line K562 (Horton et al., 1983 ) and the cells were induced to differentiate along the erythroid and megakaryocytic lineages (Alitalo, 1990; Andersson et al., 1979) . Expression of murine Rgs18 cDNA, which is ∼90% identical to its human counterpart (NP_570138) resulted in suppression of erythroid, and stimulation of megakaryocytic, differentiation as evidenced by differentiation marker mRNA analysis and histochemical staining ( Fig. 4D-G) .
The cumulative results of these multiple approaches unequivocally demonstrate the dual role of Rgs18 in actively promoting megakaryopoiesis and in restricting erythropoiesis in both mouse and human contexts. This, in conjunction with the reciprocal expression of Rgs18 and its repressor Gfi1b, suggests that the high level of expression of Gfi1b in MEPs and erythroid cells promotes this fate by repressing Rgs18 and keeping megakaryocytic differentiation in check. However, in cells adopting a megakaryocytic fate, declining Gfi1b levels upregulate Rgs18 expression and drive differentiation of these cells.
Differential regulation of MAPK signaling by Rgs18 in erythroid and megakaryocytic cells
To delineate the underlying mechanistic alterations responsible for the phenotypes ensuing from Rgs18 manipulation, we interrogated the status of two branches of MAPK signaling in these cells. The pathways mediated by the p38 MAPK family, and the ERK1 and ERK2 (ERK1/2, also known as MAPK3 and MAPK1, respectively) are known to be impacted by G protein signaling (Goldsmith and Dhanasekaran, 2007) , and have also been implicated in erythromegakaryocytic differentiation (Geest and Coffer, 2009 ). Specifically, ERK1/2 and p38 MAPK family proteins oppositely regulate these lineages by promoting proliferation of hematopoietic (megakaryocytic) cells and differentiation of erythroid cells, respectively (Geest and Coffer, 2009) . Given that Rgs proteins attenuate G protein activation, they are known to negatively impact upon MAPK signaling (Berthebaud et al., 2005; Goldsmith and Dhanasekaran, 2007) . Accordingly, Rgs18 levels and activity were expected to correlate inversely with MAPK signaling. This was indeed found to be the case for ERK1/2 signaling in megakaryocytes (L8057 cells), where Rgs18 inhibition resulted in enhanced, and overexpression in diminished, levels of phosphorylated ERK1/2 ( pERK1/2) (Fig. 5A,B) , indicating an inverse correlation between Rgs18 expression and the activity of this MAPK pathway. Likewise, p38 MAPK phosphorylation was also sharply attenuated upon Rgs18 overexpression and enhanced upon inhibition (Fig. 5D,E ). These observations indicated that both the p38 MAPK and ERK1/2 pathways are negatively impacted by Rgs18 activity in megakaryocytes. These results were confirmed by timecourse induction experiments in L8057 cells that clearly demonstrated attenuated decay of ERK1/2 and p38 MAPK phosphorylation during differentiation in Rgs18-inhibited cells (Fig. S3) .
Although the effect of ERK1/2 signaling on the proliferation versus differentiation of megakaryoblasts is controversial, with different reports supporting its stimulation of one or the other process (Geest and Coffer, 2009; Whalen et al., 1997) , our observation of the heightened differentiation of L8057 cells following downregulation of this pathway (by Rgs18) clearly demonstrates an inverse relationship between ERK1/2 signaling and the differentiation of these cells. By contrast, reduced p38 MAPK signaling upon Rgs18 overexpression likely contributes further to the attenuation of erythroid characteristics and gene expression in these cells (Fig. 5G) .
In contrast, Rgs18 depletion in erythroid (MEL) cells, diminished pERK levels (Fig. 5C ), whereas it augmented both p38 MAPK protein and phosphorylation levels (Fig. 5F ) to co-operatively increase differentiation. Thus, the phosphorylation of p38 MAPK family proteins was similar in both lineages and correlated inversely with Rgs18 activity, whereas the pERK1/2 response was diametrically opposite in erythroid and megakaryocytic cells. Moreover, timecourse induction experiments showed that a decrease in Rgs18 levels disrupted the normal decay of these signaling cascades (Fig. S3) , likely by ectopically sustaining G protein signaling. Overall, the alterations in MAPK signaling upon Rgs18 manipulation illustrate the molecular mechanisms responsible for the corresponding phenotypic alterations in differentiation in each lineage (Fig. 5G) .
Rgs18 determines the equilibrium between Klf1 and Fli1
To investigate gene expression changes downstream of Rgs18, we interrogated expression of the mutually antagonistic transcription factors Eklf or Klf1, and Fli1 in Rgs18-manipulated cells. Klf1 and Fli1 are essential for the generation of the erythroid and megakaryocytic lineages, respectively (Drissen et al., 2005; Hart et al., 2000; Parkins et al., 1995) , and they also actively suppress alternative lineage fates downstream of MEPs (Starck et al., 2003) . Likewise, the relative abundance of these factors determines the lineage choices adopted by the progeny of these bipotent progenitors. However, how one factor gains dominance over the other and vice versa during lineage specification remains unclear. Therefore, to determine whether these factors act downstream of Rgs18, we assessed their levels in cells manipulated for the latter. In both lineages, Rgs18 levels correlated directly with Fli1, and inversely with Klf1, mRNA levels, indicating that Rgs18 arbitrates alternative fates by ultimately regulating relative Klf1 and Fli1 stoichiometries (Fig. 6A-D) . Additionally, ectopic expression of Fli1 in fetal liver cells depleted of Rgs18 'rescued' their megakaryocytic potential as evidenced by the recovery of differentiation marker expression (Fig. 6E) , histochemical staining of the doubly manipulated cells relative to controls (Fig. 6F) , recovery of megakaryocyte colony counts in methylcellulose cultures ( Fig. 6G; Fig. S4A ) and surface expression of the megakaryocytic markers CD9 and CD41 (Fig. 6H) , and confirmed the role of Fli1 downstream of Rgs18 in promoting megakaryocyte differentiation. Overall, these results establish new and important functional connections between Gfi1b, Rgs18, MAPK cascades, and relative Klf1 and Fli1 levels in charting distinct cell fates downstream of bipotential progenitors (Fig. S4C ).
DISCUSSION Rgs factors and their regulators in cellular differentiation and divergence
In this report, we have identified Rgs18 as a prominent target of Gfi1b and its co-repressor LSD1 in erythro-megakaryocytic cells. Rgs18 is stringently repressed by Gfi1b and LSD1 in erythroid cells but robustly expressed in megakaryocytes due to reduced expression of these repressors. These expression patterns then support stimulation of megakaryocytic, and suppression of erythroid, differentiation by Rgs18. These results thus introduce Rgs18 as a new arbitrator of erythro-megakaryocytic differentiation and provide a novel perspective on the regulation of their differentiation by Rgs18 and its transcriptional repressor Gfi1b. These results might appear paradoxical in light of the phenotypes of germline and conditional Gfi1b deletions, which lead to the complete abrogation of both lineages in embryos and adult mice, respectively (Saleque et al., 2002; Foudi et al., 2014) , and reports of platelet disorders in patients harboring GFI1B mutations (Aminkeng, 2014; Monteferrario et al., 2014) . However, although these reports confirm the role of Gfi1b in erythro-megakaryocytic commitment and specification, what our current observations highlight is the differential expression of, and requirement for, Gfi1b subsequent to the initial emergence of these lineages from common progenitors. Given that Gfi1b performs similar functions in fetal liver and bone marrow hematopoiesis (Foudi et al., 2014; Saleque et al., 2002) , this paradigm might also hold true for the differentiation of bone marrow progenitors. Whether Rgs18 arbitrates similar lineage divergence at other cellular branch points and/or is prototypic of the function of other Rgs proteins widely expressed in multiple tissues, hematopoietic and otherwise, are fascinating and germane questions that need to be investigated in the light of the above observations. Robust and sustained expression of Gfi1b through most of erythroid differentiation (Vassen et al., 2007) is likely required for maintaining erythroid identity and differentiation, in part by suppressing megakaryocytic gene expression, including that of Rgs18, until the erythroblast stage. In contrast, the observed decline in Gfi1b levels subsequent to this stage (Vassen et al., 2007) might be equally important for terminal maturation once the cells have progressed irreversibly along the erythroid program. By contrast, downregulation of Gfi1b is necessary earlier in megakaryopoiesis, and soon after commitment to megakaryoblasts, to enable derepression of genes like Rgs18 and perhaps others that promote differentiation of this lineage.
An earlier report has shown that Rgs18 is repressed in erythroid cells by GATA1 (Johnson et al., 2007) , although it was not determined whether this repression was maintained in megakaryocytes given that GATA1 expression is also known to be downregulated during differentiation of these cells (Dai and Murphy, 1993) . If this GATA1 repression of Rgs18 is indeed operational in erythro-megakaryocytic cells, then the Rgs18 promoter could potentially be co-operatively repressed by Gfi1b and GATA1 in erythroid cells and potently derepressed by the downregulation of both factors in megakaryocytes.
In addition to Rgs18, several other Rgs factors are derepressed to varying degrees upon loss of Gfi1b (Fig. S4B) ; of these, Rgs14 and Rgs2 are also chromatin targets of Gfi1b and its cofactors (LSD1 and Rcor1) in erythroid cells (S.S., unpublished data), whereas the derepression of Rgs16 and Rgs10 in the absence of Gfi1b might be indirect. Therefore, several Rgs factors might cooperate with Rgs18 in mediating multi-factorial stimulation of megakaryocytic over erythroid differentiation, whereas their direct or indirect repression by Gfi1b would promote the latter lineage and maintain homeostasis.
Although Rgs18 is also prominently expressed in platelets (Kim et al., 2006) , it potently inhibits platelet functions, like activation and aggregation, in these megakaryocyte derivatives by inhibiting G protein signaling (Alshbool et al., 2015; Gegenbauer et al., 2012) . Therefore, this GAP factor performs pleiotropic and even opposite functions in megakaryopoiesis versus thrombopoiesis.
Lineage-specific regulation of MAPK signaling by Rgs18
Several studies have demonstrated the role of p38 MAPK family proteins and ERK1/2 signaling in the regulation of hematopoietic stem and progenitor cell expansion and differentiation (Geest and Coffer, 2009; Whalen et al., 1997) . However, their relationship with upstream or downstream transcription factors, and the processes regulated by them, continue to remain nebulous. The observations reported here now establish coherent connections between the erythro-megakaryocytic transcription factor Gfi1b and MAPK pathways through regulation of G protein signaling mechanisms. They further extend the signaling chain to reveal regulation of downstream factors Klf1 and Fli1 by these pathways. Previously, manipulation of Rgs16, but not Rgs18, has been found to impact on MAPK signaling in megakaryocytes (Berthebaud et al., 2005) , and our results now clearly illustrate the effect of Rgs18 manipulation on p38 MAPK and ERK1/2 signaling in both erythroid and megakaryocytic cells. This apparent discrepancy between the earlier results and our current results might be a consequence of the different cell types (MO7e versus L8057 and MEL) or the assays employed in each study. Our results also provide unprecedented insights into the regulation of signal transduction, particularly MAPK pathways, by Gfi1b through its transcriptional target Rgs18. Although the mechanism(s) responsible for the differential, or even opposite effects, exerted by Rgs18 on ERK1/2 signaling in erythroid versus megakaryocytic cells remains unknown, it is likely to be a major determinant in specifying distinct outcomes in the two lineages.
Relevance of Rgs18 function to hematopoietic diseases and their control
Various lines of evidence demonstrate that Rgs18 stimulates megakaryocytic differentiation (Delesque-Touchard et al., 2014; Louwette et al., 2012) , and limits platelet aggregation and activation by turning off G q signaling (Alshbool et al., 2015; Brass and Ma, 2012; Gegenbauer et al., 2012) . We now demonstrate the key role played by this factor in ensuring erythro-megakaryocytic homeostasis by actively suppressing the former and promoting the latter. These insights could be utilized to rectify imbalances between them that lead to hematopoietic abnormalities. Accordingly, a deficit in erythropoiesis could conceivably be compensated for by inhibiting Rgs18 (or other Rgs proteins that work similarly and co-operatively in these cells) and/or by indirectly stimulating G protein signaling.
Conversely, thrombocytopenias resulting from ectopic and excessive G protein signaling could be offset by stimulating Rgs18 expression or activity thereby rolling back G protein signaling.
In conclusion, our study presents Rgs18 as a dual regulator of erythro-megakaryocytic differentiation, downstream of the transcription factor Gfi1b. These effects are mediated by differential MAPK signaling and alterations in the Klf1 to Fli1 ratio. As mentioned above, these molecular insights on the generation of erythroid and megakaryocytic cells from MEPs could also provide rational platforms for developing strategies for stimulating one or the other lineage when depleted by diseases or environmental assaults.
MATERIALS AND METHODS
ChIP
ChIP experiments were performed in MEL and L8057 cells as previously described (Chowdhury et al., 2013; Saleque et al., 2007) with anti-Gfi1b (Sc8559, Santa Cruz Biotechnology) and anti-LSD1 (ab17721, Abcam) antibodies. Primers used for qPCR amplification of ChIP DNA were: Rgs18 promoter (upstream), 5′-TCATTTCCTTCAACAATTCAGTAC-A-3′ and 5′-CGAATCTTTCCTCAGATTTTTCTTA-3′; Rgs18 promoter (downstream), 5′-ATGTGTGAATCAAAAGAGAAAACTTT-3′ and 5′-CACAGATATTCATCAATCATGCTACTT-3′; and Sµ, 5′-CTTGA-GCCAAAATGAAGTAGACTGT-3′ and 5′-ACAGTCCAGTGTAGG-CAGTAGAGTT-3′.
Plasmid construction and expression
Murine Rgs18 cDNA (accession number NM_022881) was PCR amplified with the primers: 5′-ATGTCACTGGTTTTCTTCTCTCAATT-3′ and 5′-TAACCAAATGGCAACATCTGACTTTACAT-3′ from total RNA from L8057 cells and sub-cloned into pEF4/myc-His vector (Invitrogen) and pCDH-MSCV™ vector (Systems Biosciences). Fli1 (accession number NM_008026) cDNA was also PCR amplified from L8057 RNA with the primers 5′-ATGGACGGGACTATTAAGGAGGCT-3′ and 5′-GTAT-GGGTAGTAGCTGCCTAAGTGTGAAGG-3′ and subcloned into pCDH. Inserted cDNAs were verified by sequencing and protein expression was confirmed in 293T cells. Commercially available RGS18 shRNAs were purchased from the Mission™ collection (Sigma-Aldrich) and were as follows: RGS18 shRNA1 (coding), 5′-CCGGCTCCTGAAGAAGCAGT-GAAATCTCGAGATTTCACTGCTTCTTCAGGAGTTTTTG-3′; RGS18 shRNA2 (3′UTR), 5′-CCGGAGTAATGTCACATCTAGTTTGCTCGA-GCAAACTAGATGTGACATTACTTTTTTG-3′; and RGS18 shRNA3 (3′UTR), 5′-CCGGCATCATCTATCTTCCGAAATACTCGAGTATTTC-GGAAGATAGATGATGTTTTTTG-3′.
Cell culture and cell line production
Stable overexpression lines were generated by nucleofection (Amaxa) of Rgs18 pEF4/myc-His vector into L8057 (megakaryoblastic cell line) (Ishida et al., 1993) and MEL (murine erythroleukemia) (Friend et al., 1971) followed by zeocin (0.5 mg/ml) selection. Stable Rgs18-shRNA-expressing (knockdown) cell lines were created as previously described (Upadhyay et al., 2014) . MEL cells were induced to differentiate with 1.5% dimethylsulfoxide (DMSO) for 4 days and L8057 cells were induced with 50 nM 12-O-tetradecanoyl phorbol-13-acetate (TPA) for 5 days. K562 cells (ATCC CCL243) (Horton et al., 1983) were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum and antibiotics and induced to differentiate into erythroid and megakaryocytic cells by treatment with 2 mM sodium butyrate and 50 nM TPA, respectively (Alitalo, 1990; Andersson et al., 1979) . Uninduced and induced cells were harvested as needed for protein and RNA collection or histological staining.
Culture and manipulation of fetal liver cells
Total or sorted fetal liver cells (∼10 5 ) from embryonic day 12.5 (e12.5) embryos were harvested and cultured directly or transduced with lentiviruses carrying Rgs18 cDNA, Rgs18 shRNA and/or Fli1 cDNA. Cells were differentiated either in liquid culture or in a semi-solid methylcellulose medium (M3234; Stem Cell Technologies) along the erythroid or megakaryocytic lineages by culturing in erythropoietin (2 U/ml) and stem cell factor (SCF, 25 ng/ml), or thrombopoietin (20 ng/ml), IL-3 (10 ng/ml) and SCF (10 ng/ml), respectively; and selected with puromycin (0.5-1 µg/ ml). Cells were harvested from liquid culture for various assays and megakaryocyte colonies counted in methylcellulose cultures.
Animal husbandry and manipulation
All mice were maintained, manipulated and euthanized in the CCNY vivarium according to the approved CCNY IACUC (Institutional Animal Care and Use Committee) protocol. 6-8-week-old wild-type or mutant mice were subject to timed matings to obtain staged embryos for tissue (blood, yolk sac and fetal liver) collection as discussed above.
Preparation of cell lysates and western blotting
Harvested cells were lysed in whole-cell lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA and 1% Triton X-100) supplemented with 1 mM PMSF, protease inhibitors (Sigma) and phosphatase inhibitors (eBioscience) as needed. Lysates were resolved on SDS-PAGE, and western blotted with specific antibodies. Antibodies used were anti-Gfi1b (Sc8559, Santa Cruz Biotechnology), anti-LSD1 (ab17721, Abcam) and anti-Rgs18 (ab25917, Abcam) antibodies, and anti-ERK1/2 (4695), anti-pERK1/2 (4370S), anti-p38 MAPK (2371) and anti-phosphorylated-p38 MAPK (4511S) antibodies from Cell Signaling Technologies.
qPCR, histological assays and flow cytometry
Total RNA was isolated and quantified by qPCR in an ABI 7500 machine (Applied Biosciences). Marker expressions were normalized to that for hypoxanthine phosphoribosyl transferase (HPRT). The data for all qPCR reactions represents the mean±s.d. from three independent experiments. P-values were calculated by one-way analysis of variance (ANOVA) (for comparison of three or more datasets) or by multiple t-test (for two datasets) followed by Holm-Sidak post-hoc test as applicable, for comparisons. P<0.05 was considered statistically significant and has, therefore, not been indicated in any Figs. Murine and human qPCR primer sequences have either been reported previously (Saleque et al., 2007) or are listed in Table S1 .
For histochemical analysis, 10 5 cells were cyto-centrifuged and stained for benzidine, acetylcholine esterase and with May Grunwald Giemsa as previously described (Saleque et al., 2002) . The number of positively staining cells relative to total for a fixed area were determined using the ImageJ™ cell imaging and counting software (Schneider et al., 2012) . For flow cytometric analyses of surface markers, ≥10 5 cells were stained with FITC-conjugated anti-mouse CD9 or CD71 antibodies and APC-conjugated anti-mouse CD41 or Ter119 antibodies (eBioscience), respectively, and analyzed on the BD LSRII Analyzer (Becton Dickinson). For FACS sorting, cells were labeled with lin-FITC and c-Kit-phycoerythrin and the lin − c-Kit + population collected following elimination of dead cells, doublets and aggregates (gates P1-P3) on a BD FACS Aria sorter (Becton Dickinson).
